AD is a growing market with an impressive pipeline of new products from current and future players in the field.

However, none of the PDE4 inhibitors tested so far has reached the market, mainly owing to tolerability issues such as emesis. A study in Nature Biotechnology that sheds light on the structural ...

Anticipating a rising need for individually wrapped vial medication manufacturing, The Ritedose Corporation, Inc. (Ritedose) ...

Meanwhile, Staquis represents a first-in-class steroid-free topical PDE4 inhibitor for the treatment of mild-to-moderate atopic dermatitis in patients three months of age and older ³,⁴.

Sustained positive preliminary data from all completed single ascending dose (SAD) cohorts, multiple ascending dose (MAD) cohorts, and food ...

There's already stiff competition in the oral psoriasis category, however, from drugs with different mechanisms of action, including Amgen's PDE4 inhibitor Otezla (apremilast) – already making ...

The Details: Palisade Bio said the findings demonstrated PALI-2108 exhibited efficient ex-vivo conversion into its active PDE4 inhibitor form in stool samples from both normal healthy volunteers ...